Compare CMPX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | JYNT |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | 39 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.5M | 138.0M |
| IPO Year | 2020 | 2014 |
| Metric | CMPX | JYNT |
|---|---|---|
| Price | $5.20 | $8.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $14.43 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.7M | 59.7K |
| Earning Date | 03-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 133.93 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $117,696,356.00 |
| Revenue This Year | N/A | $3.73 |
| Revenue Next Year | $677.91 | $0.78 |
| P/E Ratio | ★ N/A | $42.95 |
| Revenue Growth | N/A | ★ 15.49 |
| 52 Week Low | $1.33 | $7.50 |
| 52 Week High | $6.88 | $13.47 |
| Indicator | CMPX | JYNT |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 34.99 |
| Support Level | $4.86 | $7.50 |
| Resistance Level | $5.86 | $8.77 |
| Average True Range (ATR) | 0.29 | 0.38 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 15.53 | 15.50 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.